Namrata Sangwan

All Publications

• Whole Nerve Electrophysiology and Analyses of A-alpha/beta, A-delta, and C Fiber Action Potentials. Current protocols Flippen, A., Dubus, M., Dugan, M., Catapusan, M. R., Sangwan, N., Klukinov, M., Pacharinsak, C., Yeomans, D., Anderson, T. 2025; 5 (8): e70190

  Abstract

  Ex vivo whole peripheral nerve electrophysiology provides a powerful tool for evaluating the effects of current and potential clinical treatments on nerve impulse transmission. It allows quantitative assessment of nerve conduction through compound action potential (AP) recordings, which can be correlated with sensory and motor changes. However, existing literature lacks a comprehensive methodology for isolating and analyzing APs from individual nerve fiber subtypes (e.g., A-alpha/beta, A-delta, and C fibers). This article details the optimal setup conditions and nerve stimulator parameters required to capture APs from specific nerve fibers reliably and provides a detailed and systematic approach for their analysis. © 2025 Wiley Periodicals LLC. Basic Protocol 1: Setup conditions for obtaining individual nerve fiber action potentials Basic Protocol 2: Nerve handling and parameters for optimal nerve health Basic Protocol 3: Nerve stimulation to obtain nerve fiber action potentials Support Protocol 1: Parameters for A-alpha/beta fiber stimulation and recording Support Protocol 2: Parameters for A-delta and C fiber stimulation and recording Basic Protocol 4: Quantitative analysis of nerve fiber action potentials Support Protocol 3: A-alpha/beta fiber analysis Support Protocol 4: A-delta fiber analysis Support Protocol 5: C fiber analysis.

  View details for DOI 10.1002/cpz1.70190

  View details for PubMedID 40772835

• Therapeutic potential of 6BIO and DKK1-LRP6 inhibitor in Wnt/beta-catenin pathway modulation for amyloid-beta-induced Alzheimer's disease model. Journal of Alzheimer's disease : JAD Prajapat, M., Sarma, P., Kaur, G., Choudhary, G., Jain, S., Kamal, R., Bains, O., Sangwan, N., Prakash, A., Medhi, B. 2025: 13872877251362787

  Abstract

  BackgroundThe Wnt/beta-catenin signaling pathway plays a crucial role in central nervous system development, with emerging evidence linking its dysregulation to the progression of Alzheimer's disease (AD).ObjectiveThis study investigates the activation of Wnt signaling by targeting GSK3beta and the DKK1/LRP6 interaction using a combination of 6BIO (6Bromoindirubin-3-oxime) and a novel gallocyanine derivative (8e) modulator.MethodsWe identified the interaction energy scores of both modulators with target proteins through an in-silico approach. Furthermore, the effects of 6BIO (10 M) and 8e (20 M) were assessed in SH-SY5Y cells treated with Abeta1-42 (20 M). The efficacy of these modulators was also evaluated in male Wistar rats through dose-ranging studies. An Alzheimer's disease model was established via intracerebroventricular injection of Abeta1-42, followed by treatment with 6BIO (23.8 g/kg/day, i.p.) and 8e (4.2 mg/kg/day, i.p.).ResultsBoth modulators demonstrated favorable binding energy scores and dynamic simulation results against the targeted proteins. In Abeta1-42-treated SHSY5Y cells, the combination of 6BIO and 8e significantly reduced reactive oxygen species production and apoptotic activity while modulating protein expression. In vivo study, rats treated with combination of 6BIO and 8e modulators exhibited improved neurobehavioral activity compared to AD model rats, along with altered expression of DKK1, beta-catenin, p-tau, and pGSK3beta. Additionally, decreased oxidative stress and apoptosis markers.ConclusionsThese findings suggest that the combined targeting of GSK3beta and LRP6 represents a promising therapeutic strategy for AD. The combination of 6BIO and 8e shows potential as a novel modulator and warrants further investigation in clinical trials to assess its therapeutic efficacy.

  View details for DOI 10.1177/13872877251362787

  View details for PubMedID 40734473